White Matter Abnormalities Track Disease Progression in Multiple System Atrophy.

Autor: Raghavan S; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Lesnick TG; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Castillo AM; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Reid RI; Department of Information Technology, Mayo Clinic, Rochester, MN, USA., Fought AJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Thostenson KB; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Johnson Sparrman KL; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Gehrking TL; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Gehrking JA; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Sletten DM; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Low PA; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Singer W; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Vemuri P; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Jazyk: angličtina
Zdroj: Movement disorders clinical practice [Mov Disord Clin Pract] 2024 Sep; Vol. 11 (9), pp. 1085-1094. Date of Electronic Publication: 2024 Jun 24.
DOI: 10.1002/mdc3.14147
Abstrakt: Background: White matter (WM) abnormalities have been implicated in clinically relevant functional decline in multiple system atrophy (MSA).
Objective: To identify the WM and gray matter (GM) abnormalities in MSA and assess the utility of longitudinal structural and diffusion changes as surrogate markers for tracking disease progression in MSA.
Methods: Twenty-seven participants with early MSA [15 with clinically predominant cerebellar (MSA-C) and 12 with clinically predominant parkinsonian features (MSA-P)] and 14 controls were enrolled as a part of our prospective, longitudinal study of synucleinopathies. Using structural magnetic resonance imaging (MRI) and diffusion MRI (diffusion tensor and neurite orientation and dispersion density imaging), we analyzed whole and regional brain changes in these participants. We also evaluated temporal imaging trajectories based on up to three annual follow-up scans and assessed the impact of baseline diagnosis on these imaging biomarkers using mixed-effect models.
Results: MSA patients exhibited more widespread WM changes than GM, particularly in the cerebellum and brainstem, with greater severity in MSA-C. Structural and diffusion measures in the cerebellum WM and brainstem deteriorated with disease progression. Rates of progression of these abnormalities were similar in both MSA subtypes, reflecting increasing overlap of clinical features over time.
Conclusion: WM abnormalities are core features of MSA disease progression and advance at similar rates in clinical MSA subtypes. Multimodal MRI imaging reveals novel insights into the distribution and pattern of brain abnormalities and their progression in MSA. Selected structural and diffusion measures may be useful for tracking disease progression in MSA clinical trials.
(© 2024 International Parkinson and Movement Disorder Society.)
Databáze: MEDLINE
Externí odkaz: